Parmax Pharma — 360° view

Parmax Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹12 crore and net profit of ₹0.17 crore for the September 2026 quarter.

Parmax Pharma (BSE: PARMAX) closed at ₹135.10 on 16 Nov 2026, up 322.2% over the past year. Its market capitalisation is ₹93 crore.

Share price
₹135.10 (16 Nov 2026)
Market cap
₹93 Cr (16 Nov 2026)
Revenue
₹12 Cr (September 2026 quarter)
Net profit
₹0 Cr (September 2026 quarter)
ROCE
-76.6% (FY26)
ROE
% (FY26)
Book value
₹13.6 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹139.10 / ₹22.60 (16 Nov 2026)
1-year return
322.2% (to 16 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: PARMAX

Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.